{
    "organizations": [],
    "uuid": "1d17eecb532b0df3978fe7cac743a19afe1a5803",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/merck-lungcancer/merck-kgaa-pfizers-immunotherapy-fails-in-lung-cancer-trial-idUSF9N0NT023",
    "ord_in_thread": 0,
    "title": "Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "FRANKFURT, Feb 15 (Reuters) - Merck KGaA and Pfizerâ€™s cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.\nThe results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of cancer immunotherapies.\nMerck shares turned negative following the news, trading 1.1 percent lower. (Reporting by Ludwig Burger; Editing by Edward Taylor)\n ",
    "published": "2018-02-15T21:34:00.000+02:00",
    "crawled": "2018-02-16T17:02:12.002+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "frankfurt",
        "feb",
        "reuters",
        "merck",
        "kgaa",
        "pfizer",
        "cancer",
        "drug",
        "bavencio",
        "could",
        "shown",
        "improve",
        "survival",
        "lung",
        "cancer",
        "patient",
        "previously",
        "undergone",
        "unsuccessful",
        "chemotherapy",
        "merck",
        "said",
        "result",
        "revealed",
        "thursday",
        "mark",
        "another",
        "setback",
        "drug",
        "late",
        "starter",
        "rapidly",
        "evolving",
        "field",
        "cancer",
        "immunotherapy",
        "merck",
        "share",
        "turned",
        "negative",
        "following",
        "news",
        "trading",
        "percent",
        "lower",
        "reporting",
        "ludwig",
        "burger",
        "editing",
        "edward",
        "taylor"
    ]
}